Last reviewed · How we verify
long-acting injectable risperidone
At a glance
| Generic name | long-acting injectable risperidone |
|---|---|
| Also known as | Risperdal (oral) & Risperdal Consta |
| Sponsor | Seattle Institute for Biomedical and Clinical Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
- Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse
- High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone (PHASE4)
- Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone (PHASE1)
- A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (PHASE3)
- A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities (PHASE4)
- A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings (PHASE4)
- Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |